Search

Displaying results 3731 - 3740 of 8010 in total
  1. Drug

    Neovastat

    go.drugbank.com/drugs/DB05387
    Investigational

    Neovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases … It is currently in international Phase III trials for renal cell carcinoma and non-small-cell lung cancer.

  2. Drug

    Iodoxamic acid

    go.drugbank.com/drugs/DB13539
    Experimental

    Radiopaque medium used in the diagnosis of gall bladder & bile duct diseases, usually as meglumine salt.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    IONIS-FGFR4Rx

    go.drugbank.com/drugs/DB16198
    Investigational

    IONIS-FGFR4Rx is under investigation in clinical trial NCT02476019 (A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients).

  4. Drug

    HKI-357

    go.drugbank.com/drugs/DB13002
    Investigational

    Hki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).

  5. Drug

    Ethyl biscoumacetate

    go.drugbank.com/drugs/DB08794
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)

    Categories: Vitamin K Antagonists
  6. Drug

    Gavorestat

    go.drugbank.com/drugs/DB16707
    Investigational

    Gavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).

  7. Drug

    AZD0543

    go.drugbank.com/drugs/DB33982
    Experimental

    AZD0543 is under investigation in clinical trial NCT07824622 (Study of Safety and PK of AZD0543 in Healthy Adults).

  8. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    It was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].

  9. Drug

    KB001

    go.drugbank.com/drugs/DB05222
    Investigational

    KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated

  10. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179] … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for

    Categories: Experimental Unapproved Treatments for COVID-19